Pentoxifylline added to mesalamine for ulcerative colitis
Tests pentoxifylline with mesalamine in adults with ulcerative colitis, a long-lasting bowel inflammation.
Plain-language title generated from the registry record
Registry title: Pentoxifylline in Patients With Ulcerative Colitis
Key facts
- Where
- Al Fayyum, EgyptSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with mild or moderate ulcerative colitis. It tests pentoxifylline.
- Age
- 18 to 70 years
- Sex
- Men and women can join.
- Disease stage
- Mild or moderate ulcerative colitis. People with severe ulcerative colitis cannot join.
- Earlier treatment
- People taking rectal or systemic steroids, immunosuppressives or biological therapies cannot join.
Main reasons for not taking part
- Severe ulcerative colitis
- Diabetes
- Colorectal cancer
- Significant liver or kidney function problems
- Breast feeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07349472, who can take part
Where in Egypt
- Fayoum UniversityAl Fayyum, EgyptContact: Ehab Hassan, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ihab Elsayed Hassan
- Trial code
- NCT07349472
- Record updated
- 15 April 2026
- Original description
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.Read full original descriptionShow less
Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Inclusion: Age ≥ 18 years; Both male and female will be included; Negative pregnancy test and effective contraception; Mild and moderate UC patients.
Exclusion: Patients taking rectal or systemic steroids; Patients taking immunosuppressives or biological therapies; Addiction to alcohol and / or drugs; Colorectal cancer patients; Known allergy to the studied medications; Breast feeding; Significant liver and kidney function abnormalities; Diabetic patients; Patients with severe UC.